IVIVC from Long Acting Olanzapine Microspheres
نویسندگان
چکیده
منابع مشابه
IVIVC from Long Acting Olanzapine Microspheres
In this study, four PLGA microsphere formulations of Olanzapine were characterized on the basis of their in vitro behavior at 37°C, using a dialysis based method, with the goal of obtaining an IVIVC. In vivo profiles were determined by deconvolution (Nelson-Wagner method) and using fractional AUC. The in vitro and in vivo release profiles exhibited the same rank order of drug release. Further, ...
متن کاملIVIVC of parenteral PLGA microspheres
There have been only a dozen parenteral extended release formulations that are designed to deliver drugs from a week up to 6 months since the first introduction of Lupron Depot® made of poly(lactic-coglycolic acid) (PLGA) microspheres in 1989. All parenteral extended release formulations are made of PLGA in the form of microspheres, solid implants, and in situ forming implants. Over the past fe...
متن کاملLong-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison
BACKGROUND In schizophrenia, medication adherence is critical to achieve better patient outcomes and to avoid relapses, which are responsible for a significant proportion of total healthcare costs for this chronic illness. The aim of this study was to assess the cost-effectiveness of olanzapine long-acting injection (OLAI) compared with risperidone long-acting injection (RLAI) in patients with ...
متن کاملLong-acting injectable antipsychotics: focus on olanzapine pamoate
Medication non-adherence in patients with schizophrenia continues to be a significant problem and threatens successful treatment outcomes. Medication non-adherence is often associated with negative consequences, including symptom exacerbation, more frequent emergency room visits, re-hospitalizations and relapse. Long-acting injectable (LAI) forms of antipsychotics allow for rapid identification...
متن کاملPharmacokinetics of olanzapine long-acting injection: the clinical perspective
Olanzapine long-acting injection (OLAI) is a sustained-release depot antipsychotic for the treatment of schizophrenia in adults. Our objective was to explain the pharmacokinetics of OLAI to provide clinical insight. Simulation models and data from clinical trials are presented. Olanzapine concentrations were observed immediately upon injection. Half-life was ∼30 days, controlled by the slow rat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Biomaterials
سال: 2014
ISSN: 1687-8787,1687-8795
DOI: 10.1155/2014/407065